TRAF4 is a critical molecule for Akt activation in lung cancer

Cancer Research

Volumn 73, Issue 23, 2013, Pages 6938-6950

  Li, Wei ^a,b   Peng, Cong ^a,c   Lee, Mee Hyun ^a   Lim, DoYoung ^a   Zhu, Feng ^a   Fu, Yang ^a,d   Yang, Ge ^a,d,e   Sheng, Yuqiao ^a,d,e   Xiao, Lanbo ^b   Dong, Xin ^b   Ma, WeiYa ^a   Bode, Ann M ^a   Cao, Ya ^b   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Central South University   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^e ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84890290884     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0913     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Katlic MR, Facktor MA, Berry SA, McKinley KE, Bothe A Jr, Steele GD Jr. ProvenCare lung cancer: a multi-institutional improvement collaborative. CA Cancer J Clin 2011;61:382-96.
3. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011;61:91-112.
4. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-14.
5. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002;111:293-303.
6. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
7. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
8. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97.
9. Memmott RM, Dennis PA. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res 2010;16:4-10.
10. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
11. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010;9:487-97.
12. Lin K. The Akt DUBbed InAktive. Sci Signal 2013;6:pe1.
13. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009;325:1134-8.
14. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 2012;149:1098-111.
15. Kedinger V, Rio MC. TRAF4, the unique family member. Adv Exp Med Biol 2007;597:60-71.
16. Blaise S, Kneib M, Rousseau A, Gambino F, Chenard MP, Messadeq N, et al. In vivo evidence that TRAF4 is required for central nervous system myelin homeostasis. PLoS ONE 2012;7:e30917.
17. Regnier CH, Masson R, Kedinger V, Textoris J, Stoll I, Chenard MP, et al. Impaired neural tube closure, axial skeleton malformations, and tracheal ring disruption in TRAF4-deficient mice. Proc Natl Acad Sci U S A 2002;99:5585-90.
18. Shiels H, Li X, Schumacker PT, Maltepe E, Padrid PA, Sperling A, et al. TRAF4 deficiency leads to tracheal malformation with resulting alterations in air flow to the lungs. Am J Pathol 2000;157:679-88.
19. Regnier CH, Tomasetto C, Moog-Lutz C, Chenard MP, Wendling C, Basset P, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 1995;270:25715-21.
20. Bieche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC, Lidereau R. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res 1996;56:3886-90.
21. Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MC, de Bruin PC, Oudejans JJ, et al. Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2012;135:49-58.
22. Camilleri-Broet S, Cremer I, Marmey B, Comperat E, Viguie F, Audouin J, et al. TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 2007;26:142-7.
23. Sax JK, El-Deiry WS. Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem 2003;278:36435-44.
24. Fukushima T, Matsuzawa S, Kress CL, Bruey JM, Krajewska M, Lefebvre S, et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci U S A 2007;104:6371-6.
25. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 2007;282:4102-12.
26. Jensen JP, Bates PW, Yang M, Vierstra RD, Weissman AM. Identification of a family of closely related human ubiquitin conjugating enzymes. J Biol Chem 1995;270:30408-14.
27. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 1999;96:12436-41.
28. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-37.
29. Abell AN, Johnson GL. MEKK4 is an effector of the embryonic TRAF4 for JNK activation. J Biol Chem 2005;280:35793-6.
30. Marinis JM, Hutti JE, Homer CR, Cobb BA, Cantley LC, McDonald C, et al. IkappaB kinase alpha phosphorylation of TRAF4 downregulates innate immune signaling. Mol Cell Biol 2012;32:2479-89.
31. Marinis JM, Homer CR, McDonald C, Abbott DW. A novel motif in the Crohn's disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. J Biol Chem 2011;286:1938-50.
32. Zepp JA, Liu C, Qian W, Wu L, Gulen MF, Kang Z, et al. Cutting edge: TNF receptor-associated factor 4 restricts IL-17-mediated pathology and signaling processes. J Immunol 2012;189:33-7.
33. Esparza EM, Arch RH. TRAF4 functions as an intermediate of GITR-induced NF-kappaB activation. Cell Mol Life Sci 2004;61:3087-92.
34. Mathew SJ, Rembold M, Leptin M. Role for Traf4 in polarizing adherens junctions as a prerequisite for efficient cell shape changes. Mol Cell Biol 2011;31:4978-93.
35. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
36. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small cell lung cancer. Nat Rev Cancer 2010;10:760-74.
37. Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65.
38. Peng C, Zhu F, Wen W, Yao K, Li S, Zykova T, et al. Tumor necrosis factor receptor-associated factor family protein 2 is a key mediator of the epidermal growth factor-induced ribosomal S6 kinase 2/cAMP-responsive element-binding protein/Fos protein signaling pathway. J Biol Chem 2012;287:25881-92.
39. Lee NK, Lee SY. Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J Biochem Mol Biol 2002;35:61-6.
40. Yin Q, Lin SC, Lamothe B, Lu M, Lo YC, Hura G, et al. E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol 2009;16:658-66.
41. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010;465:1084-8.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
43. Yecies JL, Manning BD. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 2011;71:2815-20.
44. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 2005;70:363-74.
45. Sommermann TG, O'Neill K, Plas DR, Cahir-McFarland E. IKKbeta and NF-kappaB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res 2011;71:7291-300.